Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

EIK1005-002: Een klinisch onderzoek naar EIK1005, een Werner-helicaseremmer, als monotherapie en in combinatie met pembrolizumab bij deelnemers met gevorderde solide tumoren inclusief tumoren met hoge microsatelliet-instabiliteit (MSI-H)

29 oktober 2026 bijgewerkt door: Eikon Therapeutics

Een multicenter, multi-part, fase 1/2-studie van EIK1005 als monotherapie en in combinatie met pembrolizumab bij deelnemers met gevorderde solide tumoren, inclusief checkpointremmer-naïeve deelnemers met microsatellietinstabiliteit hoog (MSI-H) of mismatch-repair-deficiënte (dMMR) tumoren

The goal of this clinical trial is to determine the most effective dose of EIK1005 that a person can take safely. Additionally, this study will test how well EIK1005 is tolerated alone and in combination with pembrolizumab in treating patients with advanced cancer.

Studie Overzicht

Gedetailleerde beschrijving

This Phase 1/2 study (EIK1005-002) will investigate the safety and tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary clinical activity of EIK1005 as a monotherapy and in combination with pembrolizumab in participants with advanced solid tumors, including participants with Microsatellite Instability High (MSI-H) or Mismatch Repair Deficient (dMMR) Tumors.

The study will be conducted in 2 parts: Part 1 and Part 2, with Part 1 being further divided into Part 1A and Part 1B as described below:

  • Part 1A (monotherapy dose escalation): participants will receive EIK1005 only.
  • Part 1B (combination dose escalation): participants will receive EIK1005 in combination with pembrolizumab.
  • Part 2 (dose optimization): participants will be randomized 1:1 to monotherapy with EIK1005 at one of the two selected doses from Part 1A to identify the dose of EIK1005 in monotherapy for subsequent studies.

Studietype

Ingrijpend

Inschrijving (Geschat)

160

Fase

  • Fase 2
  • Fase 1

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studiecontact

Studie Contact Back-up

Studie Locaties

    • New South Wales
      • Saint Leonards, New South Wales, Australië
        • Nog niet aan het werven
        • GenesisCare North Shore (Oncology)
      • Waratah, New South Wales, Australië
        • Werving
        • Calvary Mater Newcastle Hospital
    • Victoria
      • Ballarat, Victoria, Australië
        • Werving
        • Grampians Health
      • Camperdown, Victoria, Australië
        • Werving
        • Chris O'Brien Lifehouse (Sydney Cancer Centre)
      • Frankston, Victoria, Australië
        • Werving
        • Peninsula and Southeast Oncology (PASO) Medical
      • Frankston, Victoria, Australië, 3199
        • Werving
        • Oncology Clinics Victoria (OCV) - Cabrini Brighton Hospital
      • Brussels, België, 1020
        • Werving
        • Centre Hospitalier Universitaire Brugmann - Victor Horta
      • Berlin, Duitsland, 13125
        • Werving
        • Helios Klinikum Berlin-Buch
      • Hamburg, Duitsland, 22297
        • Werving
        • Norddeutsches Studienzentrum fur Innovative Onkologie (NIO) Hamatologisch Onkologische Praxis Eppendorf (HOPE)
    • Bavaria
      • Deggendorf, Bavaria, Duitsland, 94469
        • Werving
        • DONAUISAR Klinikum
      • Kuopio, Finland, 70210
        • Werving
        • Kuopio University Hospital
    • Rhone
      • Pierre-Bénite, Rhone, Frankrijk, 69310
        • Werving
        • Hospices Civils De Lyon (hcl) -Centre Hospitalier Lyon-Sud
      • Rome, Italië, 00128
        • Werving
        • Campus Bio-Medico di Rome University
      • Wellington, Nieuw-Zeeland
        • Werving
        • Health New Zealand
    • Manawatu
      • Roslyn, Manawatu, Nieuw-Zeeland, 4414
        • Werving
        • Palmerstone North Hospital
      • Oslo, Noorwegen, 0379
        • Werving
        • Oslo University
      • Linz, Oostenrijk, 4020
        • Werving
        • Ordensklinikum Linz Elisabethinen
      • Krakow, Polen, 31-864
        • Werving
        • GCPMED Sp. z o.o., Centrum Medyczne iMed24
      • Lodz, Polen, 90-338
        • Werving
        • Centrum Terapii Wspolczesnej J.M. Jasnorzewska Spolka Komandytowo-Akcyjna
    • West Pomeranian Voivodeship
      • Szczecin, West Pomeranian Voivodeship, Polen, 70-419
        • Werving
        • One Day Med
      • Lisbon, Portugal, 1649-028
        • Werving
        • Hospital de Santa Maria
      • Loures, Portugal, 2674-514
        • Werving
        • Unidade Local de Saúde (ULS) Loures Odivelas
      • Porto, Portugal, 4200
        • Werving
        • Instituto Português de Oncologia do Porto Francisco Gentil, E.P.E. (IPO Porto)
    • Lisbon District
      • Lisbon, Lisbon District, Portugal, 1500-650
        • Werving
        • Hospital da Luz Lisboa
      • Singapore, Singapore, 119074
        • Werving
        • National University Hospital (NUH)
    • Central Region
      • Singapore, Central Region, Singapore, 168583
        • Werving
        • National Cancer Centre Singapore (NCCS)
      • Barcelona, Spanje, 08023
        • Werving
        • START - Barcelona
      • Logroño, Spanje, 26006
        • Werving
        • START Rioja - Hospital de San Pedro
      • Madrid, Spanje, 28233
        • Werving
        • NEXT Madrid HUQSM
      • Zaragoza, Spanje, 50009
        • Werving
        • Hospital Universitario Miguel Servet
    • Balearic Islands
      • Palma, Balearic Islands, Spanje, 07120
        • Werving
        • Hospital Universitari Son Espases
    • Barcelona
      • Barcelona, Barcelona, Spanje, 8036
        • Werving
        • Hospital Clinic Barcelona
    • California
      • Los Angeles, California, Verenigde Staten, 90027
        • Werving
        • California Research Institute (CRI)
    • Florida
      • Doral, Florida, Verenigde Staten, 33172
        • Werving
        • Omnicure Clinical Research
      • Hialeah, Florida, Verenigde Staten, 33013
        • Werving
        • Bioresearch Partner
      • Plantation, Florida, Verenigde Staten, 33322
        • Werving
        • Florida Clinical Trials Group
      • Tamarac, Florida, Verenigde Staten, 33321
        • Werving
        • Florida Clinical Trials Group - Tamarac
    • New Jersey
      • Morristown, New Jersey, Verenigde Staten, 07960
        • Werving
        • Morristown Medical Center
    • New York
      • Lake Success, New York, Verenigde Staten, 11042
        • Werving
        • START New York-Long Island
      • New York, New York, Verenigde Staten, 10022
        • Werving
        • Memorial Sloan Kettering Cancer Center (MSKCC)
    • Texas
      • Fort Worth, Texas, Verenigde Staten, 76104
        • Werving
        • START Dallas Fort Worth
      • Houston, Texas, Verenigde Staten, 77030
        • Werving
        • University of Texas MD Anderson Cancer Center
      • Seoul, Zuid -Korea, 02841
        • Werving
        • Korea University Anam Hospital
      • Suwon, Zuid -Korea, 16499
        • Werving
        • Ajou University School of Medicine & Graduate School of Medicine
    • Busan
      • Busan, Busan, Zuid -Korea, 48108
        • Werving
        • Inje University-Haeundae Paik Hospital

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

18 jaar en ouder (Volwassen, Oudere volwassene)

Accepteert gezonde vrijwilligers

Nee

Geslachten die in aanmerking komen voor studie

Allemaal

Beschrijving

Key Inclusion Criteria:

  1. is ≥ 18 years of age at the time of signing the informed consent.
  2. has a life expectancy of at least 3 months.
  3. has histologically or cytologically documented advanced (unresectable and/or metastatic) solid tumor. Part 1A: recommend that participants have archival tissue not more than 3 years old. Part 1B and Part 2: participant has locally confirmed Microsatellite Instability High (MSI-H) or Mismatch Repair Deficient (dMMR) tumor. Participant must have archival tumor tissue (not more than 3 years old) for retrospective confirmation of MSI-H or dMMR tumor by a central laboratory.
  4. In Part 1A, has received and then progressed after or is intolerant to at least 1 standard treatment regimen in the advanced setting. The participant does not have alternative therapeutic options per PI's medical judgement. Preference should be given to: (1) participants with MSI-H or dMMR cancers that have progressed after checkpoint inhibitor (CPI) therapy and (2) participants with microsatellite stable cells (MSS) cancers that have progressed following at least one regimen of platinum, alkylating or topoisomerase containing chemotherapy.
  5. has measurable disease at baseline according to Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) as determined by the PI.
  6. has an Eastern Cooperative Oncology Group (ECOG) score of 0 to 1.
  7. has an adequate organ and marrow function.

Key Exclusion Criteria:

  1. has not recovered (i.e., to Grade ≤ 1 or to baseline) from prior anti-cancer therapy-induced adverse events (AEs).
  2. has received prior treatment with Werner (WRN) inhibitor.
  3. has a history of relevant drug hypersensitivity, ascertained or presumptive allergy/hypersensitivity to the active drug substance and/or formulation ingredients, history of serious allergic reactions leading to hospitalization, or any other allergic reaction in general.
  4. In Parts 1B and Part 2 Rescue: diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior to the first dose of study intervention.
  5. has known additional malignancy that is progressing or has required active treatment within the past 3 years.
  6. has known active central nervous system (CNS) metastases and/or carcinomatous meningitis. Participants with previously treated brain metastases may participate provided they are radiologically stable (ie, without evidence of progression) for at least 4 weeks as confirmed by repeat imaging performed during the study screening, are clinically stable and have not required steroid treatment for at least 14 days before the first dose of study treatment.
  7. has mean resting QTcF > 470 ms (men and women) obtained from triplicate electrocardiograms (ECGs).
  8. has active autoimmune disease that has required systemic treatment in the past 2 years (ie, with use of disease modifying agents, corticosteroids, or immunosuppressive drugs). Participants may enroll with the following conditions: Type 1 diabetes, hypothyroidism requiring hormone replacement, or skin disorders (vitiligo, psoriasis, or alopecia not requiring systemic treatment).
  9. has history of (non-infectious) pneumonitis/pneumonitis/interstitial lung disease that required steroids or current pneumonitis/interstitial lung disease.
  10. has active tuberculosis.
  11. has any active infections requiring systemic therapy.

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Behandeling
  • Toewijzing: Niet-gerandomiseerd
  • Interventioneel model: Sequentiële toewijzing
  • Masker: Geen (open label)

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Experimenteel: Part 1A (Dose escalation, Monotherapy)

EIK1005 will be given as monotherapy in participants without alternative treatment options.

EIK1005 is a selective inhibitor of the Werner helicase.

Experimenteel: Part 1B (Dose escalation, Combination with pembrolizumab)

EIK1005 will be given in combination with pembrolizumab to participants with Microsatellite Instability High (MSI-H) or Mismatch Repair Deficient (dMMR) solid tumors.

EIK1005 is a selective inhibitor of the Werner helicase.

Pembrolizumab is a PD-1 inhibitor.

Experimenteel: Part 2 (Dose optimization, Monotherapy)

Participants with Microsatellite Instability High (MSI-H) or Mismatch Repair Deficient (dMMR) advanced solid tumors will be randomized to receive EIK1005 monotherapy at one of the two identified doses selected from Part 1A.

EIK1005 is a selective inhibitor of the Werner helicase.

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Dose-Limiting Toxicity (DLT) - Part 1
Tijdsspanne: 21 Days

A DLT is a protocol-defined adverse event occurring during the DLT observation period.

21 Days
Adverse Events (AEs) - Part 1 and Part 2
Tijdsspanne: From the time of first dose of study medication through 30 days following cessation of study treatment.

Number of participants reporting adverse events or serious adverse events.

From the time of first dose of study medication through 30 days following cessation of study treatment.

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Objective Response (OR) - Part 1 and Part 2
Tijdsspanne: Through study completion, an average of 2 years.

OR defined as participants who have a complete response [CR] or partial response [PR] by Response Evaluation Criteria in Solid Tumors [RECIST] version 1.1 as assessed by the Investigator.

Through study completion, an average of 2 years.
Duration of Response (DOR) - Part 1 and Part 2
Tijdsspanne: Through study completion, an average of 2 years.

DOR (defined as the time from the first documented evidence of CR or PR until disease progression or death due to any cause, whichever occurs first, in participants demonstrating CR or PR) by RECIST 1.1 as assessed by the Investigator.

Through study completion, an average of 2 years.
Disease Control (DC) - Part 1 and Part 2
Tijdsspanne: Through study completion, an average of 2 years.

DC defined as participants with a best overall response (BOR) of complete response (CR), partial response (PR), or stable disease (SD) by RECIST 1.1 as assessed by the Investigator.

Through study completion, an average of 2 years.
Progression-free survival (PFS) - Part 2
Tijdsspanne: Through study completion, an average of 2 years.

PFS defined as the time from randomization to the first documented disease progression by RECIST 1.1 as assessed by the Investigator or death due to any cause, whichever occurs first.

Through study completion, an average of 2 years.
Pharmacokinetic (PK) parameters of EIK1005 - AUC0-24 (Part 1 and Part 2)
Tijdsspanne: Up to 1 year

AUC0-24 (Area Under the plasma Concentration versus time curve from 0 to 24 hours): Measures total drug exposure over the first 24 hours after dosing of EIK1005 as monotherapy and in combination with pembrolizumab.

Up to 1 year
Pharmacokinetic (PK) parameters of EIK1005 - AUCtau,ss (Part 1 and Part 2)
Tijdsspanne: Up to 1 year

AUCtau,ss [Area Under the plasma Concentration versus time curve over one dosing interval (tau) at steady state]: Reflects average drug exposure during each dosing interval once the steady state has been reached for EIK1005 as monotherapy and in combination with pembrolizumab.

Up to 1 year
Pharmacokinetic (PK) parameters of EIK1005 - Cmax (Part 1 and Part 2)
Tijdsspanne: Up to 1 year

Cmax (Maximum Plasma Concentration) after dose administration of EIK1005 as monotherapy and in combination with pembrolizumab.

Up to 1 year
Pharmacokinetic (PK) parameters of EIK1005 - tmax (Part 1 and Part 2)
Tijdsspanne: Up to 1 year

tmax (the time required for the plasma concentration of the drug to reach maximum concentration after dose administration) of EIK1005 as monotherapy and in combination with pembrolizumab.

Up to 1 year
Pharmacokinetic (PK) parameters of EIK1005 - t½ (Half-life) (Part 1 and Part 2)
Tijdsspanne: Up to 1 year

Half-life (the time required for the plasma concentration of the drug to decrease by 50% after the dose administration) of EIK1005 as monotherapy and in combination with pembrolizumab.

Up to 1 year

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Onderzoekers

  • Studie directeur: Nilou Mobashery, MD, Eikon Therapeutics, Inc.

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Werkelijk)

20 januari 2026

Primaire voltooiing (Geschat)

1 maart 2029

Studie voltooiing (Geschat)

1 maart 2029

Studieregistratiedata

Eerst ingediend

10 november 2025

Eerst ingediend dat voldeed aan de QC-criteria

1 december 2025

Eerst geplaatst (Werkelijk)

3 december 2025

Updates van studierecords

Laatste update geplaatst (Werkelijk)

30 oktober 2026

Laatste update ingediend die voldeed aan QC-criteria

29 oktober 2026

Laatst geverifieerd

1 september 2026

Meer informatie

Termen gerelateerd aan deze studie

Plan Individuele Deelnemersgegevens (IPD)

Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?

JA

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Ja

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Nee

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren